Coming Soon-Dr. Steve Hall

Dr. Steve Hall

Dr. Steve Hall

Dr Steve Hall has been a friend, collaborator and mentor since I purchased Neuromics. This includes being a Neuromics’ Premier supplier of Stem Cells and Related Markers, Media and Methods. Steve is currently President at AlphaGenix, Inc.

His expertise includes developing novel products and technologies for basic and clinical research with a particular emphasis on stem cell markers, biomaterials and regenerative medicine. The biomaterials product focus involves the design and application of 3-dimensional biomaterials comprised of extracellular matrix components and peptide nanofibers that have cell culture and tissue engineering applications. In addition, the company conducts regenerative medicine research that involves basic science and translational preclinical research using stem cell regulatory network discoveries and novel preclinical studies utilizing animal models with a focus on neurological disease.

He is a contributor to: Stem Cell Therapy for Neurological Diseases Stem cell therapy for the treatment of acute and chronic neurological diseases

Harting, Matthew T., Cox, Charles S. and Hall, Stephen G.  Adult Stem Cell Therapy for Neurological Disease: Preclinical evidence for cellular therapy as a treatment for neurological disease. In Vemore and Vinoglo (eds): Regulatory Networks in Stem Cells. Humana Press, pp 561-573, (2009). More information.

Stay tuned for Steve’s backstory in June!

Consistent Human Neurons

We have featured Dr. Steve Stice here. He and his team at UGA and Aruna Biomedical are developing products that are highly desired by Neuroscience Researchers.

We are in the process of finalizing details for distributing their human neuron cultures. Here is the related press release:

ArunA Biomedical, Inc. announces alliance with Neuromics for distribution of normal human neural cells.

Athens, Georgia – - March 23, 2009 – - ArunA Biomedical, Inc., announced today an agreement with Neuromics, Inc. of Edina, MN, giving Neuromics the right to non-exclusively market and sell the ArunA hN2™ Human Neural Cells and Neural Culture Medium to support applications in neurological research.ArunA has an exclusive worldwide license to develop and commercialize neural cells derived from human embryonic stem cells (hESC), and hN2 is a second generation product from this technology. These cells offer a consistent population of normal human neural cells that the neural research and pharmaceutical market highly desires.

 “ArunA has further developed its adherent monolayer technology by creating hN2™, a normal human neural cell ideal for drug screening, toxicology studies and basic neural research, and we are pleased to have Neuromics as a distribution partner,” said David Ray, Chief Executive Officer  of ArunA Biomedical

“Neuromics growth is catalyzed by offering the unique products and expertise our customers require for research success through strategic alliances with companies like ArunA Biomedical. This relationship represents a growth opportunity for us. Their hN2™ cells fill a stated research need of the Neuroscience Community and we look forward to our customers having these cells and the related new discoveries they will help generate,” said Pete Shuster, CEO and Owner of Neuromics.

Founded in 2003, ArunA Biomedical, Inc. is a privately held biotechnology corporation dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human embryonic stem cell research for use in drug discovery and neuroscience research.

Founded in 2003, Neuromics is a privately held Bio-regents Company focusing on providing research ready and proven products and methods expertise to Neuroscience, Diabetes/Obesity, Immunology and Researchers.
This press release contains forward-looking statements regarding the company’s potential impact on scientific research and collaborations with third parties.  Certain conditions could alter the outcome or progress of these statements including but not limited to unexpected manufacturing issues, product performance and quality control/assurance issues.  Forward- looking statements are based on the opinions, beliefs and expectations of the company or individuals quoted in the press release and the company does not assume any obligation to update these forward-looking statements if circumstances change. 

Isolating and Maintaining Embryonic Stem Cells

I have featured Steve Stice and his team at ArunA Biomedical and UGA. They are pioneers in developing Embryonic Stem Cell Based Cultures and Assays for Drug Discovery and Basic Research. Given the importance of their work, I am commited to keeping my finger on the pulse of their advances and discoveries.

Here they isolate, and maintain in culture, neural progenitors demonstrating properties of these neural epithelial cells from WA09 human embryonic stem cells (hESCs):


Steve Stice-The Professor Entrepreneur

Dr Steve Stice and Human Stem Cells

I am pleased and honored for the privilege of profiling Dr. Steve Stice.  He has a history of working in areas that are Biotechnology Headliners…from cloning to stem cells. Here I will be focusing on his current work with Human Stem Cells and Neural Progenitors  at ArunA Biomedical and The University of Georgia. As with all the News Behind the Neuroscience News, I will highlight how it could impact Neuroscience Research and Drug Discovery.

The Back Story

Where it Starts

Steve embodies a rare blend of entrepreneurship and scientific curiosity. He has been referred to in the press as “part professor; part entrepreneur”. This uniquely positions Steve to take his inventions from the lab directly to the marketplace by forming Biotechnology Companies. The DNA for ArunA comes from several of his earlier start-ups: Advanced Cell Technology and Cytogenesis (now part of BresaGen).

About Dr. Steve Stice

Dr. Steve Stice is CSO of Aruna Biomedical Inc and a Professor and Director of the Regenerative Bioscience Center and has a Georgia Research Alliance Eminent Scholar endowed chair.


Prior to joining the University of Georgia, Dr. Stice was a cofounder and Chief Scientific Officer at Advanced Cell Technology, a stem cell company.  Throughout his career he has published and lectured internationally on the topics of cloning and stem cells. 


In 2001, three of the human embryonic stem cell lines that Dr Stice’s lab derived were approved for federal funding by President Bush. In 2006, he was appointed by Gov. Perdue to the Post Natal Cord Blood Commission for the state of Georgia.


Dr. Stice founded Aruna Biomedical, Inc., and in cooperation with Millipore Inc. was first group to market a product derived from human embryonic stem cells (2007). The product is a neural stem cell used for research on neurological diseases and disorders, ranging from Parkinson’s disease to depression.


Contact Information:

As co-founder and CSO of Advanced Cell Technology, he has helped commercialize discovery platforms that could enable the application of stem cell technologies to the field of regenerative medicine to bring effective therapies to patients suffering from degenerative diseases like age-related macular degeneration. The company recently passed the milestone of  successfully. restoring visual function in rats through the implantation of RPE cells derived from human embryonic stem cells and in early 2008, completed pre-IND meetings with the FDA. Yes, Human Stem Cell based therapies have the potential to make the blind  see.

This bring us to ArunA. I am excited about their current and future products because their is a pent up need for them by the Neuroscience Research community which includes many of Neuromics’ Customers.

The ArunA Biomedical Story
Steve started ArunA in 2003. It actually sprung from a frustrating aspect of using Stem Cells for research. They are infinitely useful but hard to grow in cultures and differentiate into the research required cell types. Steve became acutely aware of this from his work starting in 2001 including a 5 day course he taught at NIH. Steve understood that most researchers do not want to spend the time and related frustrations associated with  this exercise. It is kind of like building a computer so you could enjoy the benefits of the web. In other words, Neuroscientists could care less about undifferentiated stem cells. At the very least, they want pure and healthy Neural Progenitors. These can then be expanded and differentiated into specific neurons. For example an ALS Researcher would be interested in making Motor Neurons; a Parkinson’s Researcher, Dopamanergic Neurons and a Pain Researcher, GABAmanergic. Nirvana for these researchers would be having pure cultures of these Neuron types at their fingertips.

Current Products

There is good news. Neuroscientists can now easily and inexpensively get human neural progenitor cells for Drug Discovery, Toxicity and Basic Research.

ENStem-A ™, Neural Progenitor Expansion Kit
hN2™, ArunA Human Neural Cell Kit 

So what was once difficult and frustrating, is now easy and convenient. Buy the kits and here’s an example of what you get.

What is Next

Knowing the needs and wants of the marketplace, ArunA’s products and capabilities excite me. Any tools that have they capabilities to bring researchers a steps closer to discovering cures for insidious Neuro-diseases need to be embraced. All of us have or will be touched by these diseases.

In my conversations with Steve, I am impressed with his clear understanding of how to evolve ArunA’s product to increase their value proposition. Available soon could be cultures developed to fit the niche needs of specific researrch areas like Parkinson’s, Pain’s and Alzheimer’s. I plan on communicating these evolutions here and at my company’s website @

Dr. Steve Stice Podcast

Inteview with Steve Stice.

Podcast by ClearCast

This Podcast gives is a good primer on Embryonic Stem Cells (ESCs)…where they come from, how they are used and the promise they have for helping researchers cure human diseases.

The listener will gain insight how ECSs when manipulated into mature neuronal cell lines can accelerate the pace of neurological research for scientists working on treatments for spinal cord injuries and neurological diseases such as Parkinson’s, Huntington’s, Alzheimer’s, ALS and possibly even depression.

On Deck-Dr. Steve Stice

We read about the promise of stem cells in the news every day. They could prove to be ”magic bullets” for curing diseases like Alzheimer’s. Parkinson’s, MS and others. Stem Cell Research is also surrounded with controversy as currently cells are often harvested from human embryos and fetuses.I believe top researchers will prove to be the voice of reason in the human stem cell debate as they are the ones best positioned to know the risks, limitations and potential.  

For our August Profile, I am honored to be featuring Dr. Steve Stice. I have had the pleasure of working with Dr. Stice both in his role as Professor and Director of the Regenerative Bioscience Center and Research Alliance Eminent Scholar endowed Chair at the University of Georgia and as Founder and Chief Scientific Officer at Aruna Biomedical.

He has over 16 years of research and development experience in biotechnology and is a co-founder of five biotechnology companies.  He was named one of the 100 Most Influential Georgians by Georgia Trend magazine.  He produced the first cloned rabbit in 1987 and the first cloned transgenic calves in 1998 (George and Charlie).  In 1997 his group produced the first genetically modified embryonic stem cell derived pigs and cattle.  This research led to publications in Science and Nature journals, national news coverage (CBS, NBC, ABC and CNN) and the first US patents on cloning animals and cattle embryonic stem cells.  In 2001, Dr. Stice announced the first cloned animal (calf) from an animal that was dead for 48 hours.  In 2005, his stem cell group published the first work on deriving motor neurons from stem cells.  Motor neurons are damaged lost during the progression of several diseases such as ALS and spinal muscular atrophy.  Throughout his career he has published and lectured on cloning and stem cell technologies.  Prior to joining the University of Georgia, Dr. Stice was a co-founder and Chief Scientific Officer at Advanced Cell Technology, a company developing cloning and stem cell technology.

Here is What is  Currently Hot in the Stice Lab:
New neural stem cells technology developed in my lab was transferred to a commercial entity, Aruna biomedical. This is the first commercialized product derived from human embryonic stem cell using federally approved stem cell lines.

  • We have produced neurons that have neural functions
  • We are working with the Navy to use our neural cells as biosensors for environmental toxins 
  • We have vascular stem cells that have characteristics that may make them suitable for  transplantation
  • We collaborate with a new company call Aruna BioMedical  that will stem cells for neural research and drug discovery
  • Developed a method to test new compounds for Alzheimer’s disease using our neural stem cell
  • We are one of five NIH stem cell training centers and have taught Scientists from Georgia to Bombay India new stem cell techniques
  • In Georgia, we produced over 50 cloned calves and 100 cloned pigs.
  • We were also the first to produce a clone from an animal that had been dead for 48 hours. This opens new opportunities in agriculture and preserving endangered species.